IPHA
Innate PharmaIPHA
IPHA
About: Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Employees: 179
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
13% more funds holding
Funds holding: 8 [Q3] → 9 (+1) [Q4]
0.13% less ownership
Funds ownership: 0.29% [Q3] → 0.17% (-0.13%) [Q4]
53% less capital invested
Capital invested by funds: $545K [Q3] → $255K (-$290K) [Q4]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$11
393%
upside
Avg. target
$11
393%
upside
High target
$11
393%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 190 met price target | 393%upside $11 | Buy Reiterated | 24 Apr 2025 |
Financial journalist opinion
Based on 7 articles about IPHA published over the past 30 days
Neutral
Business Wire
17 hours ago
Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2024 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 30, 2025. It can be downloaded (in French) on the Company's website and on the AMF's website. The Company also announced today the fil.
Neutral
Business Wire
1 day ago
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. Nectin-4 targeting is validated by enfortumab vedotin (EV), an ADC with a monomethyl auristatin E (MMAE) payload,.
Neutral
Business Wire
1 week ago
Innate Pharma Announces €15M Investment by Sanofi
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscribed by Sanofi. As announced on April 23, 2025, and given the satisfactory market conditions, Sanofi has agreed to subscribe to 8,345,387 new ordinary shares of Innate, at a price of €1.7974 per share, representing a total capital increase of €14,999,998.59 (€417,269.35 in nominal amount and €14,582,729.24 o.
Neutral
Business Wire
1 week ago
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Collaboration and License Agreement (the “2016 Agreement”) with Sanofi: As previously disclosed and in alignment with its current strategic priorities, Sanofi will opt to pursue the development of SAR'514/IPH6401 (BCMA ANKET®) in autoimmune indications under the terms of the 2016 License Agreement; In alignment.
Neutral
Business Wire
2 weeks ago
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma proposes to its shareholders to transform its corporate governance structure into a board of directors and to change its composition.
Neutral
Business Wire
2 weeks ago
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 22, 2025.
Neutral
Business Wire
4 weeks ago
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in the 2025 Stifel Virtual Targeted Oncology Forum.
Neutral
Seeking Alpha
1 month ago
Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA ) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ET Company Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - CEO Yannis Morel - COO Sonia Quaratino - CMO Frederic Lombard - CFO Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C.
Neutral
Business Wire
1 month ago
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release. “Our strategy is clear: drive innovation through our ANKET® NK-cell engager platform and accelerate our ADC programs. We are making strong clinical progress, with our lead proprietary ANKET®, IPH6501 ad.
Neutral
Business Wire
1 month ago
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois. In addition, Jonathan Dickinson, CEO of Innate Parma, will present.
Charts implemented using Lightweight Charts™